VENTANA® MET (SP44) RxDx IHC Assay for non-squamous, non-small cell lung cancer (NSQ-NSCLC)
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of cancer-related death worldwide in both men and women. NSCLC represents approximately 80-85% of all new lung cancer cases. Patients diagnosed with advanced NSCLC often face a poor prognosis, with median survival of less than one year. The VENTANA MET (SP44) RxDx Assay is the first FDA-approved immunohistochemistry (IHC) assay to identify patients with non-squamous, non-small cell lung cancer (NSQ-NSCLC) who are eligible for MET-targeted treatment with Emrelis™ (telisotizumab vedotin).
MET (also called tyrosine-protein kinase MET or c-MET) is a heterodimeric receptor tyrosine kinase encoded by the MET proto-oncogene located on chromosome 7q21-q31 and is expressed on the surface of various epithelial cells, which makes the MET protein an actionable target for antibody drug conjugates (ADCs). MET serves as a predictive biomarker for the likelihood of response to MET-targeted therapy for patients with NSCLC. Furthermore, MET protein overexpression is found in approximately 25% of advanced EGFR wild-type NSQ-NSCLC patients and is often associated with poor prognosis.
VENTANA MET (SP44) RxDx Assay uses rabbit monoclonal anti-MET antibody (clone SP44) for stating. The staining in NSQ-NSCLC exhibits a membranous and/or cytoplasmic pattern. The staining signal intensity is classified as strong, moderate, weak, or negative based on membranous and/or cytoplasmic localization. In NSQ-NSCLC, tumor cells stained with VENTANA MET (SP44) RxDx Assay are evaluated for percentage of tumor cells exhibiting strong (3+) intensity. Strong staining intensity is characterized by dark brown to black staining of the membranes and/or cytoplasm. Strong staining membranes and/or cytoplasm are easily detectable at low power magnifications such as 2x or 4x. NSQ-NSCLC tissue cases are considered positive for MET status if ≥ 50% of viable tumor cells demonstrate strong membranous and/or cytoplasmic staining. MET overexpression by IHC is considered a predictive biomarker for response to MET-targeted therapy. In the LUMINOSITY trial, patients selected by this assay who had MET overexpression and received Emrelis showed measurable clinical responses and a median duration of response of 7.2 months.
- As an aid in identifying NSQ-NSCLC patients who may be eligible for treatment with Emrelis™ (telisotuzumab vedotin)
- Companion diagnostic for therapy selection and therapeutic planning based on MET expression status
Positive (MET overexpression): ≥50% of viable tumor cells with strong (3+) membrane and/or cytoplasmic staining. Patients may be eligible for MET-targeted therapy (Emrelis).
Negative (MET low / not overexpressed): <50% of cells show strong staining; not classified as MET overexpression and likely ineligible for therapy under current indication. Not Evaluable (N/E): Insufficient tumor content, poor tissue quality, artifacts, or technical issues that prevent reliable interpretation.
Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue, including biopsies, resections, or cell block preparations.
Stability
FFPE is stable at room temperature for longer.
- J Clin Oncol. 2024 Sep 1;42(25):3000-3011. [PMID: 38843488]
- Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48. [PMID: 21102609]
- Clin Cancer Res. 2017 Feb 15;23(4):992-1000. [PMID: 27573171]
- Onco Targets Ther. 2020 Mar 25;13:2491-2510. [PMID: 32273721]
- Roche. VENTANA MET (SP44) RxDx Assay, US Package Insert. 2025.